COVID-19 Notice: 
Novo Nordisk Information and Resources. Click here.

For adult patients with type 2 diabetes, treated with diet and exercise.

When pills are no longer enough

REALIZE THE POTENTIAL WITH OZEMPIC®

Ozempic®—the only type 2 diabetes treatment with greater A1C and weight results vs Trulicity® (in SUSTAIN 7),b and study-titrated Lantus®, and as an add-on to basal insulin1,2

Ozempic® is indicated to reduce the risk of MACE for adults with T2D and established CVD1,a

Ozempic® is indicated to reduce the risk of MACE for adults with T2D and established CVD1,a

primary_msg

aMajor adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke.
bSUSTAIN 7 included 0.5 mg and 1.0 mg doses for Ozempic® and 0.75 mg and 1.5 mg doses for Trulicity®.
cWeight change was a secondary endpoint in clinical trials.
dResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial for patients with T2D and established CVD.

T2D=type 2 diabetes; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; CV=cardiovascular; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MI=myocardial infarction.

Ozempic® is indicated to reduce the risk of MACE for adults with T2D and established CVD1,a

Pen shown delivers doses of 0.25 mg or 0.5 mg.

Ozempic®—the only type 2 diabetes treatment with greater A1C and weight results vs Trulicity® (in SUSTAIN 7),b and study-titrated Lantus®, and as an add-on to basal insulin1,2

Unmatched glycemic control

Learn about glycemic control with Ozempic®

Superior results vs Trulicity® (in SUSTAIN 7)b and as an add-on to basal insulin and statistically significant results vs study-titrated Lantus®.1,2

Significant weight reduction1,2,c

Learn about glycemic control with Ozempic®

Ozempic® is not indicated for weight loss.

Significant reduction in risk of MACE1,a,d

Learn about glycemic control with Ozempic®

Evaluated in a 2-year CVOT vs placebo in adults with type 2 diabetes and established CVD.

primary_msg

aMajor adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke
bWeight change as a secondary endpoint in clinical trials.
cResults apply to Ozempic(r) plus standard of care vs standard of care alone in SUSTAIN 6 trial

T2D=type 2 diabetes; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; CV=cardiovascular; MI=myocardial infarction.

aMajor adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke.
bSUSTAIN 7 included 0.5 mg and 1.0 mg doses for Ozempic® and 0.75 mg and 1.5 mg doses for Trulicity®.
cWeight change was a secondary endpoint in clinical trials.
dResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial for patients with T2D and established CVD.

T2D=type 2 diabetes; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; CV=cardiovascular; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MI=myocardial infarction.

Resources for starting patients

Whether you’re starting your patients on Ozempic® in person or via telehealth, use these quick links to find all the resources you need.

Get resources »

secondary_msg
Dr Pratley
EXPLORE EXPERT INSIGHTS

Ozempic® vs Trulicity®

Learn about the results of a head-to-head trial of 2 once-weekly GLP-1 RA therapies from one of the primary investigators.

Dive into the study »

Help patients realize the potential with Ozempic®

Help patients realize the potential with Ozempic®

Check your patients’ coverage and view savings offer

See details »

Request Ozempic® samples

6-week samples are available

Request samples »    

Selected Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®.

Ozempic® (semaglutide) injection 0.5 mg or 1 mg Indication and Limitations of Use

Ozempic® (semaglutide) injection 0.5 mg or 1 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CV disease.

  • Ozempic® has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
  • Ozempic® is not a substitute for insulin. Ozempic® is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
  • Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®.

Contraindications

  • Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known hypersensitivity to semaglutide or to any of the product components.

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be referred to an endocrinologist for further evaluation if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
  • Pancreatitis: Acute and chronic pancreatitis have been reported in clinical studies. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® promptly, and if pancreatitis is confirmed, do not restart.
  • Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
    Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
  • Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
  • Hypoglycemia: The risk of hypoglycemia is increased when Ozempic® is used in combination with insulin secretagogues (eg, sulfonylureas) or insulin.
  • Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Ozempic® in patients reporting severe adverse gastrointestinal reactions.
  • Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist.

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation.

Drug Interactions

  • The risk of hypoglycemia may be lowered by a reduction in the dose of the secretagogue or insulin.
  • Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.

Use in Specific Populations

  • There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.

Please click here for Prescribing Information, including Boxed Warning.

 

References:

  1. Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk Inc; January 2020.
  2. Pratley RE, Aroda VR, Lingvay I, et al, on behalf of the SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. 

Return to top ▴